Considering that NKG2A antibody (monalizumab) has already been in numerous clinical trials on treatment of rheumatoid arthritis, cancer and stem-cell transplantation65, a combined NKG2A checkpoint treatment and DAA therapy would avoid the risk of late relapse or reinfection after achieving a sustained virological response via DAA therapies. Here, KLRC1 is linked to rheumatoid arthritis.